Pro-Dex, Inc.
30.71+2.00 (+6.97%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · PDEX · USD
Key Stats
Market Cap
100.73MP/E (TTM)
11.50Basic EPS (TTM)
2.67Dividend Yield
0%Recent Filings
8-K
Pro-Dex FY2025 sales up 24%
Pro-Dex reported fiscal 2025 results on September 4, 2025, with net sales surging 24% to $66.6 million, driven by $12.0 million in next-generation handpiece sales to its largest customer, boosting operating income 49% to $10.7 million despite Q4 margin compression to 20% from tariff costs and product mix shifts. Net income jumped to $9.0 million, or $2.67 per diluted share, aided by $1.5 million in unrealized investment gains versus prior-year losses. Backlog hit $50.4 million. Fiscal 2026 growth looks solid.
10-K
FY2025 results
Pro-Dex's FY2025 sales surged 24% to $66.6M, propelled by a 29% jump in medical devices to $47.7M, with orthopedic revenue up 42% y/y to $33.5M on the next-gen handpiece launch, while repairs grew 13% to $18.6M amid legacy enhancements. Yet Q4 stumbled as a customer shipment hold pinched momentum, though resumption late-quarter signals rebound; gross margins expanded to 29% from 27%, fueled by volume despite $2.5M under-absorption drag. Net income soared to $9.0M from $2.1M, aided by $1.5M unrealized investment gains, with diluted EPS at $2.67 on 3.36M shares. Backlog ballooned to $50.4M, liquidity solid at $32.7M working capital plus $7.3M revolver room, while $3.5M buybacks trimmed shares. Q4 faltered, but orders accelerate.
8-K
CEO and CFO bonuses approved
Pro-Dex's Compensation Committee approved cash bonuses on August 14, 2025, for CEO Richard L. Van Kirk ($70,000) and CFO Alisha K. Charlton ($50,000), payable August 21. These rewards stem from sales growth and fiscal 2025 results surpassing targets. Bonuses signal strong execution. Yet, they highlight reliance on key leaders for ongoing momentum.
8-K
Auditor merger prompts switch
Pro-Dex's auditor Moss Adams resigned on June 3, 2025, following its merger with Baker Tilly US, LLP, which the Audit Committee promptly approved as the new independent firm. No disagreements or reportable events marred the prior audits for fiscal years 2024 and 2023. Clean transition. This ensures seamless compliance without operational hiccups.
8-K
Pro-Dex Q3 sales surge 22%
Pro-Dex reported strong fiscal 2025 third-quarter results on May 1, 2025, with net sales jumping 22% to $17.4 million, driven by $6.2 million in shipments of its largest customer's next-generation orthopedic handpiece, though offset by a $4.4 million drop in legacy products. Gross profit rose 45% to $5.8 million on favorable mix, boosting operating income 65% to $3.6 million and net income to $3.3 million, or $0.98 per diluted share—up sharply from $0.19 last year, aided by $550,000 in unrealized investment gains and a $595,000 realized gain. For the nine months, sales climbed 27% to $49.1 million, with net income hitting $7.8 million. Volatility in equity investments remains a key risk.
IPO
Website
Employees
Sector
Industry
APYX
Apyx Medical Corporation
2.95-0.15
BDX
Becton, Dickinson and Company
181.52-2.69
ECIA
Encision, Inc.
0.35+0.12
IRIX
IRIDEX Corporation
1.03+0.02
ISRG
Intuitive Surgical, Inc.
537.59-7.80
PLSE
Pulse Biosciences, Inc
17.11-0.24
PRCT
PROCEPT BioRobotics Corporation
35.93-1.02
PROF
Profound Medical Corp.
6.13-0.07
RMD
ResMed Inc.
253.62-2.95
STXS
Stereotaxis, Inc.
2.92-0.05